189 related articles for article (PubMed ID: 23957982)
1. Methylprednisolone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers.
Hirahara K; Kano Y; Sato Y; Horie C; Okazaki A; Ishida T; Aoyama Y; Shiohara T
J Am Acad Dermatol; 2013 Sep; 69(3):496-8. PubMed ID: 23957982
[No Abstract] [Full Text] [Related]
2. Possible role of TH17 cells in the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Teraki Y; Kawabe M; Izaki S
J Allergy Clin Immunol; 2013 Mar; 131(3):907-9. PubMed ID: 23083672
[No Abstract] [Full Text] [Related]
3. Systemic and local management at the onset of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications.
Sotozono C; Ueta M; Kinoshita S
Am J Ophthalmol; 2010 Feb; 149(2):354; author reply 355. PubMed ID: 20103059
[No Abstract] [Full Text] [Related]
4. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes.
Tan SK; Tay YK
Acta Derm Venereol; 2012 Jan; 92(1):62-6. PubMed ID: 21710108
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immune globulin therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis complicated by hemolysis leading to pigment nephropathy and hemodialysis.
Ririe MR; Blaylock RC; Morris SE; Jung JY
J Am Acad Dermatol; 2013 Aug; 69(2):221-5. PubMed ID: 23673282
[TBL] [Abstract][Full Text] [Related]
6. Toxic epidermal necrolysis-like subacute cutaneous lupus erythematosus.
Ryan E; Marshman G; Astill D
Australas J Dermatol; 2012 Nov; 53(4):303-6. PubMed ID: 23157783
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis in a cohort of patients.
Ao S; Gao X; Zhan J; Ai L; Li M; Su H; Tang X; Chu C; Han J; Wang F
J Am Acad Dermatol; 2022 Jun; 86(6):1236-1245. PubMed ID: 35121075
[TBL] [Abstract][Full Text] [Related]
8. Toxic epidermal necrolysis in a child successfully treated with cyclosporin A and methylprednisolone.
Aihara Y; Ito R; Ito S; Aihara M; Yokota S
Pediatr Int; 2007 Oct; 49(5):659-62. PubMed ID: 17875095
[No Abstract] [Full Text] [Related]
9. Hematological abnormalities and the use of granulocyte-colony-stimulating factor in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
Ang CC; Tay YK
Int J Dermatol; 2011 Dec; 50(12):1570-8. PubMed ID: 22098009
[TBL] [Abstract][Full Text] [Related]
10. Etanercept therapy for toxic epidermal necrolysis.
Paradisi A; Abeni D; Bergamo F; Ricci F; Didona D; Didona B
J Am Acad Dermatol; 2014 Aug; 71(2):278-83. PubMed ID: 24928706
[TBL] [Abstract][Full Text] [Related]
11. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis.
Kardaun SH; Jonkman MF
Acta Derm Venereol; 2007; 87(2):144-8. PubMed ID: 17340021
[TBL] [Abstract][Full Text] [Related]
12. Fluconazole-induced Stevens-Johnson syndrome in a HIV-negative patient.
Monastirli A; Pasmatzi E; Vryzaki E; Georgiou S; Tsambaos D
Acta Derm Venereol; 2008; 88(5):521-2. PubMed ID: 18779900
[No Abstract] [Full Text] [Related]
13. Novel complication of Flakka: Stevens-Johnson syndrome/Toxic epidermal necrolysis overlap.
İlhan B; Doğan H; Şahin EA; Karslıoğlu N; Koçak Ö
Am J Emerg Med; 2019 Mar; 37(3):562.e1-562.e3. PubMed ID: 30503281
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset.
Araki Y; Sotozono C; Inatomi T; Ueta M; Yokoi N; Ueda E; Kishimoto S; Kinoshita S
Am J Ophthalmol; 2009 Jun; 147(6):1004-11, 1011.e1. PubMed ID: 19285657
[TBL] [Abstract][Full Text] [Related]
15. Severe cutaneous adverse reactions to drugs.
Chia FL; Leong KP
Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):304-9. PubMed ID: 17620821
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.
Su SC; Mockenhaupt M; Wolkenstein P; Dunant A; Le Gouvello S; Chen CB; Chosidow O; Valeyrie-Allanore L; Bellon T; Sekula P; Wang CW; Schumacher M; Kardaun SH; Hung SI; Roujeau JC; Chung WH
J Invest Dermatol; 2017 May; 137(5):1065-1073. PubMed ID: 28011147
[TBL] [Abstract][Full Text] [Related]
17. [Ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis].
Chronopoulos A; Pleyer U; Mockenhaupt M
Klin Monbl Augenheilkd; 2012 May; 229(5):534-9. PubMed ID: 22592345
[TBL] [Abstract][Full Text] [Related]
18. Stevens-Johnson syndrome: a case report.
Yazicioglu M; Iscan B; Turgut B; Yalcin O
Allergol Immunopathol (Madr); 2009; 37(4):219-21. PubMed ID: 19912981
[No Abstract] [Full Text] [Related]
19. Genetic association of IFN-γ +874T/A polymorphism in Mexican patients with drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
Charli-Joseph Y; Lima G; Ramos-Bello D; Aguilar D; Orozco-Topete R; Llorente L
Arch Dermatol Res; 2013 May; 305(4):353-7. PubMed ID: 23224615
[TBL] [Abstract][Full Text] [Related]
20. Use of Etanercept in a Series of Pediatric Patients With Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis Spectrum Disease.
Eliades P; Fonseca M; Harp J
JAMA Dermatol; 2020 Aug; 156(8):921-922. PubMed ID: 32347889
[No Abstract] [Full Text] [Related]
[Next] [New Search]
